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Abstract
Purpose—Currently two injectable products of diethylenetriaminepentaacetic acid (DTPA) are 
U.S. Food and Drug Administration (FDA) approved for decorporation of 241Am, however, an 
oral product is considered more amenable in a mass casualty situation. The diethyl ester of DTPA, 
named C2E2, is being developed as an oral drug for treatment of internal radionuclide 
contamination.
Materials and methods—Single dose decorporation efficacy of C2E2 administered 24-hours 
post contamination was determined in beagle dogs using a 241Am nitrate inhalation contamination 
model. Single and multiple dose toxicity studies in beagle dogs were performed as part of an 
initial safety assessment program. In addition, the genotoxic potential of C2E2 was evaluated by 
the in vitro bacterial reverse mutation Ames test, mammalian cell chromosome aberration 
cytogenetic assay and an in vivo micronucleus test.
Results—Oral administration of C2E2 significantly increased 241Am elimination over untreated 
controls and significantly reduced the retention of 241Am in tissues, especially liver, kidney, lung 
and bone. Daily dosing of 200 mg/kg/day for 10 days was well tolerated in dogs. C2E2 was found 
to be neither mutagenic or clastogenic.
Conclusions—The di-ethyl ester of DTPA (C2E2) was shown to effectively enhance the 
elimination of 241Am after oral administration in a dog inhalation-contamination model and was 
well tolerated in toxicity studies.
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Introduction
In his first speech to the U.N. Security Council in New York, President Obama called 
nuclear terrorism one of the greatest threats to international security and that the 
consequences of such an attack would be enormous (Allison, 2010). This increasing threat 
has spurred the development of radionuclide decorporation agents for treatment of 
individuals contaminated with various radioactive materials; the transuranic elements Am, 
Pu and Cm are among these radionuclides of concern (International Commission on 
Radiological Protection, 1979). In 2004, trisodium calcium diethylenetriaminepentaacetate 
injection (Ca-DTPA) and trisodium zinc diethylenetriaminepentaacetate injection (Zn-
DTPA) received U.S. Food and Drug Administration (FDA) approval for the treatment of 
internal contamination with these actinides and were subsequently included in the Strategic 
National Stockpile for use in the event of mass contamination. While Ca- and Zn-DTPA 
injections have been shown to be efficacious in treating contaminated individuals (Yaes RJ, 
2004), they require administration by a skilled professional via either intravenous injection 
or via nebulization. These are not practical methods of administration in a mass casualty 
situation. This problem is particularly acute as early access to treatment improves 
decorporation efficacy by minimizing tissue deposition of the radioactive material. The loss 
of efficacy caused by treatment delay cannot be overcome by increasing the cumulative dose 
of decorporation agent (Seidel, 1975). Therefore, there is a need to develop DTPA 
formulations that can be self-administered and rapidly distributed to a large population. 
However, DTPA is known to have poor oral bioavailability (~3%) primarily because its 
charge and hydrophilicity cause permeability-limited absorption (Volf, 1984). Esterification 
is often used to overcome barriers in drug delivery such as poor solubility (Stella and Nti-
Addae, 2007) or absorption (Beaumont et al., 2003). The carboxylic acids present on DTPA 
provide multiple sites for esterification that we hypothesized could be used to increase 
lipophilicity and overcome the permeability-limited absorption.
Lipophilic promoieties have previously been added to DTPA or 
triethylenetetraminehexaacetic acid (TTHA) in order to enhance chelation of intracellular 
radionuclides, however, no studies previously focused on their use for oral bioavailability 
enhancement (Markley, 1963), (Guilmette et al., 1979), (Bruenger et al., 1992). The DTPA 
ligands were not orally administered and although the TTHA ligands were given orally, the 
research focused on the long-term removal of radionuclides from intracellular deposition 
sites. None of the polycarboxylic acid ligands investigated were more effective or less toxic 
than Ca-DTPA and most of the research was abandoned (Durbin, 2006).
Therefore with a focus on bioavalibility enhancement, a series of DTPA esters were 
synthesized, and two promising candidates emerged following evaluation of their physical-
chemical properties and permeability characteristics. These were the penta-ethyl and di-ethyl 
esters of DTPA, referred to as C2E5 and C2E2, respectively. C2E5 was shown to effectively 
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decorporate 241Am in a wound-contamination animal model (Sueda et al., 2012), (Sueda, 
2014), but its unfavorable pharmaceutical properties and concerns related to its 
hepatotoxicity caused us to focus our efforts on C2E2.
Here we report the decorporation efficacy of C2E2 following a single dose to beagle dogs 
contaminated via inhalation of americium. Americium was chosen as a model isotope for 
efficacy studies due to its wide availability and potential for use in dirty bombs. The toxicity 
of C2E2 was determined both in vitro using classical genotoxicity endpoints and in vivo by 
evaluation of both the acute and ten day maximum tolerated doses in beagle dogs.
Materials and Methods
General
Americium-241 was obtained from the Department of Energy as a nitrate complex stock 
solution. An aliquot of the stock solution was taken to dryness on a medium temperature 
hotplate and reconstituted in 0.25 M nitric acid to yield a final activity of 7.44 MBq/mL 
(201.1 µCi/mL) as determined by gamma pulse height analysis. C2E2 was prepared by first 
synthesizing DTPA bis-anhydride followed by its subsequent reflux with ethanol as 
previously described (Guilmette et al., 1979) (Yield - 85%, Purity – 97.7%).
The general procedures for animal care and housing were conducted in accordance with the 
National Research Council for the Care and Use of Laboratory Animals and the Animal 
Welfare Standards. All procedures and protocols used in animal studies were reviewed and 
approved by the Institutional Animal Care and Use Committee of Covance Laboratories Inc. 
or Lovelace Respiratory Research Institute and were performed in Association for 
Assessment and Accreditation of Laboratory Animal Care International (AAALAC) 
accredited facilities.
Beagle Inhalation Contamination Model for 241Am
Inhalation contamination was performed in a method similar to that previously described 
(Doyle-Eisele et al., 2014). The beagles were fasted, sedated (acepromazine i.m.; 0.05 mg/
kg.) and anesthetized with Isoflurane (5%) (MWI Veterinary Supply, Boise, ID, USA) prior 
to exposure to 241Am. A muzzle was fixed to the dog and placed into an exposure plenum 
where a mixture of oxygen and isoflurane was continually flowing and monitored. Aerosols 
were generated from the 241Am-nitrate solution (pH - 0.74) using a Hospitak nebulizer 
(Unomedical Inc. McAllen, Tx, USA). The aerosol was dried by transiting through a tube 
furnace (Thermo Scientific) operating at 70–80°C to minimize the amount of acid present. 
Oxygen was maintained at 45–55 % and isoflurane was delivered as needed (2–3 % in 
oxygen). Aerosol samples were collected on Pallflex Fiberfilm filters (Pall, Port 
Washington, NY, USA) and analyzed for 241Am content. Dogs were exposed to an 241Am 
aerosol atmosphere of 42.7 ± 8.3 kBq/L (1.16 ± 0.22 µCi/L) for 8 minutes. The particle size 
of the aerosol was consistent with previous inhalation studies (Doyle-Eisele et al., 2014) and 
determined to be 0.63 µm Activity Median Aerodynamic Diameter (AMAD) with a 
geometric standard deviation (GSD) of 1.72, with each dog receiving an average of 111 kBq 
(3 µCi) of 241Am.
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Single Dose Efficacy of C2E2 in Beagle Dogs
The efficacy for decorporation of 241Am by C2E2 was evaluated in beagle dogs (n = 4/sex/
dose) approximately 13 months of age (8.8 ± 1.2 kg). The dogs were acclimatized to 
metabolic cages 24 hours prior to 241Am administration. Dogs were fasted overnight prior to 
treatment. C2E2 solutions were administered by oral gavage 24 hours after contamination to 
mimic a realistic treatment delay (Cassatt et al., 2008). Dogs received either de-ionized (DI) 
water (vehicle control) or C2E2 solutions at 100, 300 or 500 mg/kg. C2E2 was dissolved in 
DI water on each day of dosing and dogs were administered between 33–52 mL of solution 
to achieve the desired dosage. Urine and feces were collected daily for analysis of 
radioactivity. Fourteen days after contamination the dogs were euthanized and necropsied. 
The liver, spleen, kidneys, lungs and both femurs were among the tissues collected and 
analyzed for radioactivity. Samples were thermally and chemically processed as previously 
described (Sueda et al., 2014), placed into 20-mL scintillation vials and the gamma pulse 
height from 241Am was analyzed in a gamma counter (2480 Wizard2 Gamma Counter, 
Perkin Elmer, Waltham, MA, USA).
Statistical analyses to evaluate the pattern of recovered doses were conducted by one-way 
analysis of variance (ANOVA). For each sample, differences between untreated controls and 
treated groups were assessed with individual F-tests based on the ANOVA’s pooled estimate 
of underlying variance between dogs.
Acute Maximum Tolerated Dose of C2E2 in Dogs
Four beagles (Covance Research Products Inc., Madison, WI, USA), (n = 2/sex/dose with 7 
day washout between doses), 8 to 10 months old (10.1 – 12.0 kg) were housed individually 
in stainless steel cages. The dogs were acclimatized to the conditions at least two weeks 
prior to the study: ad libitum access to water and certified canine diet #2027C (Harlan 
Laboratories Inc., Indianapolis, IN, USA) for 6 hours per day in a controlled environment 
with lighting on a 12-h light/dark cycle. Prior to dosing, the dogs were fasted overnight and 
food was returned 2 hours after dosing. The same dogs were used for each consecutive dose 
level with a minimum 7-day washout period between dose escalations. The initial dose of 
C2E2 administered was 100 mg/kg with subsequent escalating doses (300 or 750 mg/kg) 
based on clinical observations and clinical pathology results of the previous dose. C2E2 
solutions were prepared by dissolving in DI water to a concentration that allowed each dog 
to receive 8.3 mL/kg of dosing solution by oral gavage. In addition, the effect of food on 
toxicity was examined at a single dose level of 300 mg/kg under fed conditions.
Detailed observations were performed at 1, 2 and 4 hours post-dose and then twice daily. 
Blood was collected from the jugular vein pre-dose and at 0.5, 1, 2, 4, 6, 8, 12 and 24 hours 
for toxicokinetic analysis and approximately 48 hours post-dose for standard hematology 
and clinical chemistry analyses as well as trace element analyses. Concentrations of C2E2, 
the mono ethyl-ester of DTPA (C2E1) and DTPA were determined by liquid 
chromatography coupled with tandem mass spectrometry (LC-MS/MS) using a Thermo 
TSQ Quantum Access mass spectrometer (Waltham, MA, USA). Quantification of C2E2 
and DTPA was based on the peak areas of analyte to their respective internal standards. As a 
C2E1 standard was not available, concentrations were estimated by producing a calibration 
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curve from the 1% C2E1 impurity present in the C2E2 material. The range of quantification 
was 100 to 100,000 ng/mL for C2E2, 5 to 1,000 ng/mL for C2E1 and 10 to 1,000 ng/mL for 
DTPA. Toxicokinetic analysis was performed using WinNonlin Professional Edition 
(Pharsight Corporation, Version 5.2)
Ten-Day Oral Dose Range Finding Study of C2E2 in Dogs
Twenty beagles (Covance Research Products Inc.), (n = 2/sex/dose), 7 to 9 months old (8.4 – 
11.4 kg) were housed individually in stainless steel cages. C2E2 doses of 0, 60, 200, 400, 
and 600 mg/kg/day for 10 days in fasted dogs were selected based on the results of the oral 
acute maximum tolerated dose study. Animals were fasted overnight prior to dosing and 
certified canine diet #2027C was returned approximately 3 hours after completion of dosing. 
Water was provided ad libitum. Cageside observations were performed at 1, 2 and 4 hours 
post-dose and detailed observations were performed during the predose phase, and prior to 
dosing on days 1 and 6. As in the single dose study, blood was collected from the jugular 
vein pre-dose and at 0.5, 1, 2, 4, 6, 8, 12 and 24 hours for toxicokinetic analysis and predose, 
day 6 and at sacrifice (day 11) for standard hematology and clinical chemistry analyses.
Genotoxicity of C2E2
A reverse mutation assay in Salmonella typhimurium and Escherichia coli (Ames test), a 
chromosomal aberration assay in Chinese hamster ovary (CHO) cells and an in vivo rat bone 
marrow micronucleus assay were performed in accordance with standards established by 
International Conference on Harmonisation (ICH) guidance S2(R1) (Food and Drug 
Administration, 2012). The Ames test was conducted with Salmonella histidine auxotrophs 
TA98, TA100, TA1535, and TA1537 and the E. Coli tryptophan auxotroph WP2uvrA, using 
a plate incorporation procedure as previously described (Ames et al., 1975),(Green and 
Muriel, 1976). C2E2 was evaluated at doses of 5 to 5000 µg/plate with or without rat liver 
homogenate metabolic activation (Aroclor-induced Sprague-Dawley rat liver S9, NADP and 
Glucose-6-phosphate). Positive and vehicle controls were concurrently evaluated, and 
triplicate plates were used for all samples. Positive controls (Sigma, St. Louis, MO, USA) 
included, 2-nitrofluorene, sodium azide, ICR-191, 4-nitroquinoline-N-oxide, benzo[a]pyrene 
and 2-aminoanthracene. Dose concentration was confirmed by high-performance liquid 
chromatography (HPLC). C2E2 was considered to have produced a positive response if a 
dose-dependent increase in revertant frequency was ≥2.0-fold vehicle control values for 
strains TA98, TA100, and WP2uvrA, or ≥3.0-fold vehicle control values for strains TA1535 
and TA1537.
The chromosomal aberration assay was performed in a CHO cell line derived from an 
ovarian biopsy of a female Chinese hamster (CHO-WBL). C2E2 was prepared in cell 
culture grade water, and stocks were prepared by serial dilution in vehicle so that all 
treatments were administered into 10 mL cultures in a volume of 10%. Treatment periods 
continued for 3 hours with or without metabolic activation, or for approximately 20 hours 
without metabolic activation. Solutions containing C2E2 ranging from 7 to 500 µg/mL were 
prepared and concentrations were confirmed by HPLC. Visual observations of cultures for 
general cell health and confluence were made prior to termination. Mitomycin C (1.5 µM for 
the 3-hour treatment, and 0.6 µM for the 20-hour treatment) were used as positive controls 
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for the assays without metabolic activation (rat liver S9, NADPH and isocitric acid) and 
cyclophosphamide (19 µM) in the assay with metabolic activation. At culture termination, 
viable cells were counted and population doubling was calculated for measurement of 
cytotoxicity to support selection of dose levels for aberration analysis. For each 
concentration, 1000 cells were assessed for toxicity and at least 200 cells in metaphase were 
scored and tabulated for aberrations. To control bias, slides were identified by an 
abbreviated code unknown to the scorer. Statistical analysis employed a Cochran-Armitage 
test for linear trend and Fisher's Exact Test to compare the percentage of cells with 
aberrations in treated cells to the results obtained for the vehicle controls.
The in vitro micronucleus test was performed in male Sprague Dawley rats. C2E2 was 
formulated in cell culture grade water vehicle and the dose volume for all treatment groups 
was 20 mL/kg. Male rats were administered vehicle control or C2E2 at 500, 1000, or 2000 
mg/kg/day for two days separated by approximately 24 hours. The 2000 mg/kg high dose is 
the limit dose for this assay recommended by ICH S2(R1) guidance. A positive control 
group received a single 60 mg/kg cyclophosphamide treatment on the second day of dosing. 
Animals were observed at least twice daily for toxic signs and/or mortality. Bone marrow 
was extracted approximately 24 hours after the last treatment in all groups and at least 2000 
polychromatic erythrocytes (PCE) per animal were analyzed for the frequency of 
micronuclei. Cytotoxicity was assessed by scoring the number of polychromatic 
erythrocytes and normochromatic erythrocytes (NCE) observed while scoring at least 500 
erythrocytes per animal.
Results
Single Dose Efficacy of C2E2 in Beagle Dogs
When radionuclide exposure is conducted via the inhaled route, fractional recoveries cannot 
be calculated; therefore, the actual administered activity of 241Am must be calculated. This 
is determined based on aerosol concentration samples as well as physiological and 
radiochemical measurement data. The estimated mean delivered 241Am activity was 
calculated to be 102.5 and 95.5 kBq (2.77 and 2.58 µCi) for female and male dogs, 
respectively.
Statistically significant increases in 241Am elimination over control were observed in all 
treatment groups with the highest dose of C2E2 (500 mg/kg) producing significant increases 
in decorporation over the 300 mg/kg dose (p<0.01). As shown in Figure 1, urinary excretion 
of 241Am increased in a dose-dependent manner. Urinary excretion was 8-fold higher than 
control for 100 and 300 mg/kg doses and 13-fold higher at 500 mg/kg. At all dose levels, 
fecal elimination showed modest enhancement for three days after treatment before 
returning to control levels (Figure 2). Treatment with doses ≥ 300 mg/kg resulted in a 50 % 
increase in fecal elimination of 241Am, significantly higher than control (p<0.05).
The ability of a decorporation agent to prevent uptake of 241Am into body tissues, 
particularly the liver, kidney and bone, is also important. Significant reductions in liver, 
kidney and lung 241Am burden were observed at all dose levels (p<0.05). Figure 3 
demonstrates that a dose-dependent decrease in tissue burden was only observed in liver and 
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lung tissues. At 500 mg/kg there was >65% decrease in liver and spleen 241Am burden, 
>50% decrease in kidney and lung burden and >30% decrease in total 241Am bone content 
compared to untreated controls.
Acute Maximum Tolerated Dose of C2E2 in Dogs
Beagle dogs received single C2E2 doses of 100, 300 or 750 mg/kg under fasted conditions 
and 300 mg/kg under fed conditions. Across all groups, transient emesis, excessive 
salivation and fecal abnormalities occurred that did not affect the overall health of the dog 
and, therefore, were not considered significantly adverse. C2E2 administered at ≤ 300 mg/kg 
had no significant effects on clinical pathology test results. Two days after administration of 
750 mg/kg, two of four dogs exhibited increased alanine and aspartate aminotransferase 
(ALT and AST) activities indicating hepatocellular injury. Systemic exposure to C2E2 
(Area under the concentration time curve from 0–24 hours (AUC0–24)) generally increased 
in a dose proportional manner (Table 1), and there was no greater than a 2-fold difference in 
mean C2E2 maximum plasma concentration (Cmax) and AUC0–24 values between sexes. 
C2E2 exposure was lower under fed conditions compared to the fasted state; Cmax and 
AUC0–24 values were at least 22-fold and 7-fold lower, respectively, in fed dogs. Under fed 
conditions the fraction of C2E2 metabolized to C2E1 doubled but was only responsible for 2 
% of the total exposure. No adverse clinical observations were made in male or female dogs 
and the maximum tolerated single dose of C2E2 by oral gavage was identified as 750 
mg/kg.
Ten Day Oral Dose Range Finding Study of C2E2 in Dogs
Daily administration of C2E2 to beagle dogs by oral gavage for 10 days at doses of 60, 200, 
400 and 600 mg/kg/day resulted in the early sacrifice of one male in both the 400 and 600 
mg/kg/day groups due to weight loss and declining health. Clinical pathology identified 
hepatocellular necrosis as the cause of toxicity in these dogs. Due to these early sacrifices 
the doses ≥ 400 mg/kg/day exceed the maximum tolerated dose. Exposure to C2E2 
increased with increasing dose and no accumulation of C2E2, C2E1 or DTPA was observed 
after administration of multiple doses. As in the acute maximum tolerated dose study, 
transient emesis and/or fecal abnormalities (bulky stools, mucus in stools, loose stool or 
mild diarrhea) occurred in dogs receiving doses ≥ 200 mg/kg/day. In animals that survived 
until necroscopy, mild to moderate (1.0 – 3.6 x control) increased AST activity was 
observed on day 6 at doses ≥ 600 mg/kg/day. Mildly to markedly (6.8 – 90 x control) 
increased ALT activity was observed on days 6 and 11 in animals receiving doses ≥ 400 
mg/kg/day. The increases in AST and ALT levels were associated with microscopic 
evidence of liver injury and considered adverse. Tubule cell necrosis was present in one 
female in both the 400 and 600 mg/kg/day groups. This was not noted in the males at 
terminal sacrifice but was noted in both males sacrificed early. The liver and kidney were 
identified as the target organs of toxicity at ≥ 400 mg/kg/day. Based on these findings, an 
No-observed-adverse-effect level (NOAEL) of 200 mg/kg/day for 10 days of oral dosing in 
beagles was established.
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C2E2 was evaluated for its potential to induce reverse mutations at the histidine locus of 
Salmonella typhimurium and at the tryptophan locus of E. coli in the Ames test and for its 
ability to cause chromosome aberrations in CHO cells. These in vitro tests are required by 
the FDA for all small molecule drugs prior to their use in human clinical safety trials. 
Additionally, an in vivo rat bone marrow micronucleus test was performed to evaluate C2E2 
for clastogenic activity and/or disruption of the mitotic apparatus by detecting micronuclei 
in polychromatic erythrocytes.
The mutagenicity of C2E2 was evaluated in five bacterial tester strains at doses from 5 to 
5000 µg/plate with or without S9 activation. Compared to vehicle controls, reductions in the 
mean numbers of revertant colonies, indicative of C2E2 treatment-related toxicity, was 
noted at the 5000 µg/plate level in TA100, TA1535, TA1537 and WP2uvrA under 
conditions without S9 and at ≥ 500 µg/plate in TA1535, TA1537 and WP2uvrA under 
conditions with S9. There were no relevant increases in the number of revertant colonies 
observed at any dose level with any strain with or without S9 metabolic activation (Table 
II). All vehicle and positive control values were within acceptable ranges. Thus, C2E2 was 
not mutagenic in the Ames assay for bacterial gene mutation up to 5000 µg/plate with or 
without metabolic activation.
In the chromosome aberration assays after 3-hour exposure, either with or without metabolic 
activation, no cytotoxicity was observed as evident by no dose-related reductions in cell 
counts or calculated population doublings compared to the concurrent vehicle control. All 
vehicle and positive controls were in acceptable ranges. Chromosomal aberrations were 
analyzed from the cultures treated with 245, 350 and 500 µg/mL of C2E2 and there were no 
statistically significant increases in the number of cells with chromosomal aberrations, 
polyploidy, or endoreduplication.
For the 20-hour test chromosomal analysis, cytotoxicity was observed. Based on mitotic 
indices, the 6.92, 9.89 and 14.1 µg/mL dose levels were selected for aberration analysis. The 
14.1 µg/mL dose level produced a 53% reduction in mitotic index compared to the 
concurrent vehicle control. Chromosomal analyses again showed that there were no 
biologically relevant or statistically significant increases in the number of cells with 
aberrations observed at any dose level examined. Therefore, C2E2 was determined to be 
negative for the induction of chromosomal aberrations with and without S9 when tested up 
to cytotoxicity-limiting dose levels and the 500 µg/mL limit dose for this assay.
During the in vivo micronucleus test, one animal from the 2000 mg/kg/day group was noted 
to have audible respiration and hypoactive behavior on day 2. No other adverse signs of 
clinical toxicity were observed in any other C2E2 treated animal. There were no statistically 
significant decreases in the C2E2 treatment group PCE:NCE ratios compared to the vehicle 
control value indicating an absence of treatment-related bone marrow cytotoxicity.
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Although there has been much research investigating the decorporation of radioactive 
actinides, DTPA remains the agent of choice for elimination enhancement of internalized 
americium, plutonium and curium. Recently there has been a focus on the development of 
novel orally active chelators and improved formulations to overcome the shortcomings of 
DTPA. Tablets containing DTPA and permeation enhancers increased oral DTPA 
absorption from 5 % to 12% in rats (Shankar et al., 2013). Another approach involves the 
development of an orally administered DTPA nanoparticle formulation. Preclinical studies 
of this oral ‘NanoDTPA’™ capsule formulation demonstrated favorable pharmacokinetic 
and safety profiles in rodent and dog models (Reddy et al., 2012). Radionuclide 
decorporation efficacy was also demonstrated with a transdermally administered formulation 
of the DTPA penta-ethyl ester prodrug (C2E5), however, toxicological assessment was not 
conducted (Zhang et al., 2013a,b).
In this work we detail the development of an orally bioavailable ester of DTPA for use in 
radiological emergencies. For medical countermeasure development programs where 
efficacy can only be demonstrated in animal models, particular emphasis is placed on the 
appropriateness of the models used. Here we have demonstrated that orally administered 
C2E2 enhances urinary and fecal elimination of 241Am from beagle dogs in a model that 
was designed to mimic a realistic response to a mass casualty contamination. Specifically, 
the inhalation route of contamination was selected based on the most likely scenario for 
contamination of a large number of people, the species used was selected for the similarity 
of its 241Am biokinetics to humans, and a 24-hour delay before treatment was used to 
approximate the time at which the initial response treatment would commence. The 
clearance of radioactive particles from the lungs following inhalation exposure is a complex 
and species-dependent process (Snipes, 1989). Particle clearance can occur by a mechanical 
process (e.g. muccocilliary action) or by the dissolution and subsequent absorption of the 
radionuclide into the systemic circulation. For moderately soluble materials, such as most 
americium salts, mechanical removal is strongly species-dependent whereas dissolution-
absorption is species-independent (Bailey et al., 1989). The rate of particle clearance in dogs 
and monkeys are a better approximation of human clearance than rodents (Snipes, 1989). 
For these non-rodent species, human 241Am biokinetics in other compartments are better 
approximated in dogs (Durbin, 2006), hence their use in the present study.
The elimination of 241Am was significantly increased over controls in all treatment groups. 
Americium was predominantly eliminated by C2E2 in the urine, although statistically 
significant increases in fecal elimination were observed in the mid and high dose groups. 
This is in contrast to other studies performed with more lipophilic (C22) 
polyaminocarboxylic acids, where the predominant elimination was fecal via the biliary 
pathway (Miller et al., 2010). This difference may be attributed to a smaller increase in 
lipophilicity generated by addition of ethyl esters rather than longer alkyl chain promoieties. 
The inhalation contamination model may also mask some of the fecal elimination effects 
due to the high percentage of activity (27 %) cleared from the lung in control animals via 
mucocillary clearance.
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As efficacy cannot ethically be tested in human volunteers, proposed radionuclide 
decorporation agents need to comply with the Animal Rule (21 CFR 314.600) (Food and 
Drug Administration, 2009) for efficacy determination before receiving approval for use in 
humans. The studies described herein were performed as the initial steps to meet regulatory 
requirements to demonstrate that C2E2 is safe for first–in-human studies and efficacious for 
studies performed under the Animal Rule. Dose escalating toxicity studies were conducted 
to evaluate the acute toxicity of C2E2 and the data was used to support dose level selection 
for subsequent repeat-dose toxicity testing. The NOAEL established in dogs indicates that 
large doses of C2E2 are well tolerated. Administration of C2E2 with food resulted in a 
reduction in systemic exposure; this is an important factor that must be considered in the 
design of human clinical trials. In dogs, the liver was identified as a target organ of toxicity 
due to elevation of ALT and AST levels after a single dose of 750 mg/kg and at ≥ 400 
mg/kg after 10 daily doses. At high doses or after multiple injections, DTPA is also 
associated with liver and kidney toxicity (Fukuda, 1984 & 1987). As with DTPA, the rapid 
excretion of C2E2 in the urine, may explain some of the nephrotoxicity. On occasion, oral 
administration of C2E2 at doses ≥ 200 mg/kg/day resulted in transient emesis. Emesis in 
future studies may be minimized by formulating C2E2 in enteric coated tablets or capsules. 
Although this may delay release, it may also help to minimize loss of drug and further 
increase bioavailability.
The maximum tolerated dose of 750 mg/kg is seven fold higher than the lowest effective 
single dose tested, though upon repeat dosing the NOAEL was determined to be 200 mg/kg/
day. The therapeutic index is determined by the ratio of a drug’s effective dose and lethal 
dose. Unlike traditional diseases in which the effective dose is measured by a quantal effect, 
the goal in decorporation therapy is to maximize radionuclide removal and the effect is 
measured on a continuous scale. As with DTPA, the retention of 241Am is inversely related 
to dose; though each doubling of dose results in a diminishing return in efficacy (Lloyd RD. 
et al, 1979). Consequently a balance must be struck between decorporation efficacy and 
toxicity. To maximize the therapeutic window and maintain efficacy, a modified dose 
regimen could be used, in which a high initial dose is given followed by lower daily doses.
A comprehensive assessment of the genotoxic potential of the drug is required to obtain 
regulatory approval for human clinical trials. As no single test is capable of detecting all of 
the genotoxic mechanisms relevant to carcinogenicity, a standardized battery approach is 
recommended by ICH (Food and Drug Administration, 2012). These tests were completed 
as part of this study and the results indicate that C2E2 is not mutagenic or clastogenic.
As with DTPA, repeated dosing with C2E2 is expected to further enhance the elimination 
of 241Am. Extended daily treatment will enable chelation of radionuclides that continue to 
translocate from the lung into the systemic circulation. Besides providing ease of access to 
treatment, the oral formulation is advantageous for long-term treatment because repeated 
intravenous injections are avoided. The efficacy and acute toxicity of C2E2 in rats and 
multiple dose toxicity over 28 days in both species are currently being investigated.
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Single doses of C2E2 administered orally to dogs 24 hours after contamination by inhalation 
of 241Am nitrate significantly increased the urinary elimination and reduced the tissue 
burden of 241Am. The toxicity of acute oral doses of C2E2 was evaluated in dogs, and the 
NOAEL were identified for single and multiple dosing. C2E2 is neither mutagenic or 
clastogenic, based on the Ames test, chromosome aberration assay and micronucleus test 
data. Thus, this DTPA analog appears to be a promising orally-administered medical 
countermeasure for treatment of individuals contaminated with transuranic elements. Based 
on these studies as well as preliminary acute and genetic toxicity testing, C2E2 is a 
promising candidate for inclusion in the Strategic National Stockpile.
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Daily urinary excretion after a single oral administration of C2E2 to dogs 24 hours after 
inhalation contamination with 241Am nitrate. Each point represents the average result 
obtained from 4 dogs.
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Daily fecal excretion after a single oral administration of C2E2 to dogs 24 hours after 
inhalation contamination with 241Am nitrate. Each point represents the average result 
obtained from 4 dogs.
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Percent of respirable 241Am dose remaining in lung (A), liver (B), total bone (C) and kidney 
(D) in dogs administered different doses of C2E2 at 24 h after inhalation contamination 
with 241Am nitrate (Error bars indicate standard deviation (SD) n=4, *p<0.05 against control 
group, **p<0.01 against control group).
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